Class of Stock [Axis]
Common Stock, par value $0.007 per share
Tradeable Warrants to purchase Common Stock
Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Intangible Asset, Finite-Lived, Class [Axis]
Trademarks and Trade Names [Member]
Customer Relationships [Member]
Segments [Axis]
Single Reportable Segment [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Convertible Preferred Stock [Member]
Warrant [Member]
Restricted Stock [Member]
Product and Service [Axis]
Health Care, Patient Service [Member]
Histology Service Fees [Member]
Medical Director Fees [Member]
Department of Defense Observational Studies [Member]
Other Revenues [Member]
Legal Entity [Axis]
CyPath Lung [Member]
Long-Lived Asset, Class [Axis]
Computer Equipment [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Computer Software [Member]
Equipment [Member]
Furniture and Fixtures [Member]
Vehicles [Member]
Leasehold Improvements [Member]
Diagnostic R&D [Member]
Laboratory Services [Member]
General Corporate Activities [Member]
Lab Equipment [Member]
Computer and Software [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Second Finance Agreement [Member]
Debt Instrument [Axis]
2024 Toyota Corolla [Member]
Finance Agreement [Member]
2025 Directors and Officers Insurance Policy [Member]
Series B Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Title and Position [Axis]
Investors [Member]
Award Type [Axis]
Restricted Stock Units Unvested [Member]
Pre-funded Warrants [Member]
Plan Name [Axis]
2024 Equity Incentive Plan [Member]
2014 Equity Incentive Plan [Member]
Restricted Stock Units (RSUs) [Member]
Employees, Non-Employees and Board of Directors [Member]
Vesting [Axis]
Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Payment Arrangement, Tranche Two [Member]
Location, Statement of Income, Balance [Axis]
2014 and 2024 Equity Incentive Plan [Member]
Class of Warrant or Right [Axis]
Tradeable Warrant [Member]
Non-Tradeable Warrant [Member]
Pre-IPO Convertible Notes [Member]
IPO Tradeable [Member]
IPO Non-tradable [Member]
Direct offering March 2024 [Member]
Placement agent direct offering March 2024 [Member]
Inducement/direct offering August 2024 [Member]
Placement agent direct offering August 2024 [Member]
Direct offering October 2024 [Member]
Warrant inducement February 2025 [Member]
Public offering May 2025 [Member]
PIPE/Inducement offering August 2025 [Member]
Placement agent direct offering June 2026 [Member]
Service Agreement [Member]
Consolidated Entities [Axis]
IRTH Communication LLC [Member]
Consulting Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Information, Former Legal or Registered Name
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Accounts and other receivables, net
Inventory
Prepaid expenses and other current assets
Total current assets
Non-current assets:
Property and equipment, net
Operating lease right-of-use asset, net
Finance lease right-of-use asset, net
Goodwill
Intangible assets, net
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Unearned revenue
Operating lease liability, current portion
Finance lease liability, current portion
Notes payable, current portion
Total current liabilities
Non-current liabilities:
Operating lease liability, net of current portion
Finance lease liability, net of current portion
Notes payable, net of current portion
Total liabilities
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred Stock, par value $0.001 per share; 20,000,000 shares authorized; 450 shares and 700 shares issued and outstanding at June 30, 2026, and December 31, 2025, respectively
Common Stock, par value $0.007 per share; 350,000,000 shares authorized; 6,783,061 and 4,498,675 issued and outstanding at June 30, 2026, and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Net revenue
Operating expenses:
Direct costs and expenses
Research and development
Clinical development
Selling, general and administrative
Depreciation and amortization
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Other income
Other expense
Change in fair value of warrants issued
Total other income (expense), net
Net loss before provision for income tax expense
Income tax expense
Net loss
Net loss per common share, basic
Net loss per common share, diluted
Weighted average common shares outstanding, basic
Weighted average common shares outstanding, diluted
Balance
Balance, shares
Stock-based compensation expense
Stock-based compensation expense, shares
Sale of Common Stock
Sale of Common Stock, shares
Conversion of Preferred
Conversion of Preferred, shares
Conversion of Preferred, shares
Issuance of Stock Options
Offering costs
Net loss
Exercise of stock warrants
Exercise of stock warrants, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Fair value adjustment on warrants
Changes in operating assets and liabilities:
Accounts and other receivables
Inventory
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Unearned revenue
Operating lease right-of-use asset
Net cash used in operating activities
Cash flows from investing activities
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of Common Stock from direct offering, net of underwriting discounts, commissions, and offering expenses of $511,448 in 2026 and $112,922 in 2025
Proceeds from exercise of warrants, net of underwriting discounts, commissions, and offering expenses of $243,145 in 2025
Payment on loans payable
Principal repayments on finance leases
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Interest expense paid in cash
Income taxes paid in cash
Common Stock from direct offering, net of underwriting discounts, commissions, and offering expenses
Warrants, net of underwriting discounts, commissions, and offering expenses
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Credit Loss [Abstract]
ACCOUNTS AND OTHER RECEIVABLES, NET
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Property, Plant, and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET
Payables and Accruals [Abstract]
ACCRUED EXPENSES
Revenue Recognition and Deferred Revenue [Abstract]
UNEARNED REVENUE
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS
Leases
LEASES
Debt Disclosure [Abstract]
NOTES PAYABLE
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Equity [Abstract]
CONVERTIBLE PREFERRED AND COMMON STOCK
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION
Warrants
WARRANTS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Use of Estimates
Principles of Consolidation
Cash and Cash Equivalents
Concentration of Risk
Advertising Expense
Loss Per Share
Revenue Recognition
Property and Equipment
Intangible Assets
Recent Accounting Pronouncements
Segment Information
Research and Development
Accrued Research and Development Costs
Regulatory Matters
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES
SCHEDULE OF REVENUE RECOGNITION
SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE
SCHEDULE OF INTANGIBLE ASSETS
SCHEDULE OF ESTIMATED AMORTIZATION OF INTANGIBLE ASSETS
SCHEDULE OF SEGMENT INFORMATION
SCHEDULE OF ACCOUNTS AND OTHER RECEIVABLES
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
SCHEDULE OF PROPERTY AND EQUIPMENT
SCHEDULE OF ACCRUED EXPENSES
SCHEDULE OF COMPONENTS OF LEASE EXPENSE
SCHEDULE OF BALANCE SHEET INFORMATION RELATING TO LEASES
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT UNDER NON-CANCELLABLE
SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS
SUMMARY OF OPTION ACTIVITY
SUMMARY OF RESTRICTED STOCK AWARD
SCHEDULE OF CLASS OF WARRANT
Accumulated deficit
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Total net revenue
Patient services fees
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Cost
Accumulated amortization
Total finite-lived intangible assets, net
2026
2027
2028
2029
2030
Thereafter
Total
Total operating loss
Non-operating (expense), net
Net loss before income tax expense
Income tax expense
Federal insured limit
Advertising expense
Finite-lived intangible asset, useful life
Amortization of intangible assets
Number of operating segments
Number of not disclosed reportable segments
Patient service fees
Histology service fees
Medical director fees
Other receivables
Total accounts and other receivables, net
Schedule Of Prepaid Expenses And Other Current Assets
Prepaid insurance
Legal and professional
Other
Total prepaid expenses and other current assets
Property and equipment, gross
Less: accumulated depreciation and amortization
Total property and equipment, net
Depreciation expense
Compensation
Legal and professional
Clinical
Other
Total accrued expenses
UnearnedRevenueTable [Table]
UnearnedRevenueLineItems [Line Items]
Unearned revenue
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Operating lease, remaining lease term
Finance lease, remaining lease term
Imputed interest, rate
Schedule Of Components Of Lease Expense
Amortization of right-of-use asset - finance lease
Interest on lease liabilities - finance lease
Operating lease cost
Total lease cost
Operating cash paid from finance leases
Operating cash paid from operating leases
Schedule Of Balance Sheet Information Relating To Leases
Operating lease right-of-use, assets
Operating lease liability, current
Operating lease liability, non-current
Total operating lease liabilities
Finance lease right-of-use asset, gross
Accumulated amortization
Finance lease liability, long-term
Total finance lease liabilities
Weighted-average remaining lease term, operating leases (in years)
Weighted-average remaining lease term, finance leases (in years)
Weighted-average discount rate, operating leases
Weighted-average discount rate, finance leases
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Remaining for 2026
2027
2028
2029
2030
2031 and thereafter
Total undiscounted cash flows
Less discounting
Present value of lease liabilities
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Remaining for 2026
2027
2028
2029
2030
2031 and thereafter
Total undiscounted cash flows
Less discounting
Present value of lease liabilities
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Face amount
Maturity date
Bears fixed interest rate
Debt instrument periodic payment
Notes payable
Notes payable, current
Short-term financing
Interest rate
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Newly designated series B convertible preferred stock
Convertible preferred stock, stated value
Preferred stock issued shares
Par value per share
Number of shares converted
Conversion price per share
Warrants to purchase
Common stock exercise price
Common stock exchanged
Conversion price reduced
Common stock, par value per share
Shares issued
Unvested restricted stock
Common stock, value
Payments of sales price percentage
Shares issued
Gross proceeds from common stock
Sale of stock per share
Gross proceeds from Offering
Prefunded warrants exercised
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, outstanding, beginning balance
Weighted-average exercise price outstanding, beginning balance
Weighted-average remaining contractual term (in years), outstanding
Aggregate intrinsic value outstanding, beginning balance
Number of options, granted
Weighted-average exercise price, granted
Weighted-average remaining contractual term (in years), granted
Number of options, exercised
Weighted-average exercise price, exercised
Number of options, forfeited
Weighted-average exercise price, forfeited
Number of options, outstanding, ending balance
Weighted-average exercise price outstanding, ending balance
Aggregate intrinsic value outstanding, ending balance
Number of options, outstanding, vested and exercisable
Weighted-average exercise price, vested and exercisable
Weighted-average remaining contractual term (in years), vested and exercisable
Aggregate intrinsic value, vested and exercisable, ending balance
Number of restricted stock awards, Balance
Weighted-average grant price, Balance
FMV on grant date, Balance
Vested number of RSA, Balance
Unvested number of RSA, Balance
Number of restricted stock awards, Granted
Weighted-average grant price, Granted
FMV on grant date, Granted
Vested number of RSA, Granted
Unvested number of RSA, Granted
Number of restricted stock awards, Forfeited
Weighted-average grant price, Forfeited
FMV on grant date, Forfeited
Vested number of RSA, Forfeited
Unvested number of RSA, Forfeited
Number of restricted stock awards, Balance
Weighted-average grant price, Ending Balance
FMV on grant date, Balance
Vested number of RSA, Balance
Unvested number of RSA, Balance
Number of shares available for grant
Number of shares authorized
Unrecognized compensation
Grant date fair value of options granted
Numbet of vested options
WarrantsTable [Table]
WarrantsLineItems [Line Items]
Warrant outstanding
Exercise price
Warrants exercised
Warrants to purchase shares
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Number of warrants issued
Weighted-average exercise price
Number of warrants exercised
Number of warrants outstanding
Subsequent Event [Table]
Subsequent Event [Line Items]
Number of shares issued, value
Number of shares issued
Shares price per share
Converted shares
Pre funded warrants convertible in to common stock
Tradeable Warrants to purchase Common Stock
Clinical development expense.
Change in fair value of warrants issued.
Adjustments to additional paid in capital issuance of stock options.
Stock issued during period value warrants exercised.
Number of warrants exercised during the current period.
Increase decrease in operating lease right of use asset.
Payments of warrant issuance costs.
CyPath Lung [Member]
Property And Equipment Useful Life [Table Text Block]
Computer Software [Member]
Finite lived intangible assets amortization expense after year four.
Accrued Research And Development Costs [Policy Text Block]
Regulatory Matters [Policy Text Block]
Patient service fees.
Histology fees.
Medical director fees.
Prepaid expenses and other current assets [Text Block]
Prepaid legal and professional.
Accrued clinical expense current.
Schedule Of Capital Leased Assset [Table Text Block]
Second Finance Agreement [Member]
2024 Toyota Corolla [Member]
Finance Agreement [Member]
2025 Directors and Officers Insurance Policy [Member]
Series B Convertible Preferred Stock [Member]
Investors [Member]
Restricted Stock Units Unvested [Member]
Payments of sales price percentage.
Pre-funded Warrants [Member]
2014 Equity Incentive Plan [Member]
2024 Equity Incentive Plan [Member]
2014 and 2024 Equity Incentive Plan [Member]
Share based compensation arrangement by share based payment award weighted average granted remaining contractual term.
Share based compensation arrangement by share based payment award fair market value options outstanding number.
Share based compensation arrangement by share based payment award fair market value options outstanding number, granted.
Share based compensation arrangement by share based payment award fair market value options outstanding number, forfeited.
Share based compensation arrangement by share based payment award options vested and expected to vest outstanding number granted.
Share based compensation arrangement by share based payment award options vested and expected to vest outstanding number forfeited.
Employees, Non-Employees and Board of Directors [Member]
Warrants Disclosure [Text Block]
Class of warrant or right number of securities exercised
Tradeable Warrant [Member]
Non Tradeable Warrant [Member]
Pre-IPO Convertible Notes [Member]
IPO Tradeable [Member]
IPO Non-tradable [Member]
Placement agent direct offering June 2026 [Member]
Number of warrants exercised.
Direct offering March 2024 [Member]
Placement agent direct offering March 2024 [Member]
Inducement/direct offering August 2024 [Member]
Placement agent direct offering August 2024 [Member]
Direct offering October 2024 [Member]
Warrant inducement February 2025 [Member]
Public offering May 2025 [Member]
PIPE/Inducement offering August 2025 [Member]
Consulting Agreement [Member]
Single Reportable Segment [Member]
Number of reportable segments not disclosed flag.
Histology Service Fees [Member]
Medical Director Fees [Member]
Department of Defense Observational Studies [Member]
Other Revenues [Member]
Diagnostic Research And Development [Member]
Laboratory Services [Member]
General Corporate Activities [Member]
Lab Equipment [Member]
Computer and Software [Member]
Research and Development Expenses [Member]
Prefunded warrants convertible to common stock.
Service Agreement [Member]
IRTH Communication LLC [Member]
Operating cash paid from finance leases.
Useful Life, Lease Term [Member]
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Interest Expense, Nonoperating
Other Nonoperating Expense
ChangeInFairValueOfWarrantsIssued
Shares, Outstanding
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Share-Based Payment Arrangement, Noncash Expense
Increase (Decrease) in Accounts and Other Receivables
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Increase (Decrease) in Deferred Revenue
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Repayments of Short-Term Debt
Finance Lease, Principal Payments
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Intangible Asset, Finite-Lived, Accumulated Amortization
Intangible Asset, Finite-Lived, after Accumulated Amortization
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
Accrued Professional Fees, Current
Other Accrued Liabilities, Current
Deferred Revenue
Lease, Cost
Operating Lease, Payments
Finance Lease, Right-of-Use Asset, Accumulated Amortization
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
Finance Lease, Liability, to be Paid, Year One
Finance Lease, Liability, to be Paid, Year Two
Finance Lease, Liability, to be Paid, Year Three
Finance Lease, Liability, to be Paid, Year Four
Finance Lease, Liability, to be Paid, after Year Five
Finance Lease, Liability, to be Paid
Finance Lease, Liability, Undiscounted Excess Amount
Sale of Stock, Number of Shares Issued in Transaction
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairMarketValueOptionsOutstandingNumber
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumberForfeited